DanielEMorgansternMD
Oncology • Plainville, CTBreast Cancer, Cancer Genetics/Cancer Risk Assessment
Clinical Assistant Professor of Medicine University of Connecticut Medical School
Dr. Morganstern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 N Mountain Rd
Ste 202
Plainville, CT 06062Phone+1 860-224-4408Fax+1 860-827-3428
Summary
- Daniel Morganstern, MD, is an oncologist based in Hartford, CT, with subspecialties in Breast Cancer and Cancer Genetics/Cancer Risk Assessment. Dr. Morganstern completed his education at the State University of New York Downstate Medical Center College of Medicine and further specialized in Hematology and Medical Oncology during his residency and fellowship at Beth Israel Deaconess Medical Center. He is well-published, with several of his papers being heavily cited, particularly in the Breast Cancer Research and Journal of Clinical Oncology. He was honoured as a Regional Top Doctor by Castle Connolly in 2014.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1991 - 1994
State University of New York Downstate Medical Center College of MedicineClass of 1991
Certifications & Licensure
CT State Medical License 2018 - 2025
MA State Medical License 1993 - 2019- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Publications & Presentations
PubMed
- 128 citationsTyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.Andreas Chott, Zijie Sun, Daniel E. Morganstern, Jing Pan, Tong Li
The American Journal of Pathology. 1999-10-01 - 30 citationsPhase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesJose Pablo Leone, Kyrre E. Emblem, Michelle Weitz, Rebecca Gelman, Bryan P. Schneider
Breast Cancer Research. 2020-11-30 - 20 citationsDocetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate CancerMary-Ellen Taplin, Wanling Xie, Glenn J. Bubley, Marc S. Ernstoff, W. V. Walsh
Journal of Clinical Oncology. 2006-12-01
Press Mentions
Starling Physicians Lead Next Era of Cancer CareJune 4th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
